Ask about this productRelated genes to: XPO1 antibody
- Gene:
- XPO1 NIH gene
- Name:
- exportin 1
- Previous symbol:
- -
- Synonyms:
- CRM1, CRM-1, emb
- Chromosome:
- 2p15
- Locus Type:
- gene with protein product
- Date approved:
- 1998-05-12
- Date modifiied:
- 2019-03-12
Related products to: XPO1 antibody
Related articles to: XPO1 antibody
- Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukemia (AML) remains unclear. This study aimed to define the role of XPO1 in AML and elucidate the mechanism by which Selinexor regulates homologous recombination (HR). - Source: PubMed
Publication date: 2026/04/23
Xu ChunliWang DandanChen RuiqiFeng XuCheng FengChen Yu - This study aimed to define the potential role of circulating tumor DNA (ctDNA) in children, adolescents, and young adults (CAYA) with classical Hodgkin lymphoma (cHL). This prospective trial was conducted in France between 2019 and 2023 and recruited CAYA patients (≤25 years old) with a new diagnosis of cHL. Patients were treated according to the EuroNet-PHL-C2 trial (EudraCT: 2012-004053-88), and plasma ctDNA evaluations were performed at diagnosis, after two cycles of chemotherapy, and in case of relapse. Two hundred and seventy-five patients were included. Median age at diagnosis was 15 years (range 2-22), and 47% of the patients were treated as advanced stages (treatment level 3 [TL-3]). Using an 18-gene amplicon-based next-generation sequencing (NGS) targeted panel encompassing the most frequently mutated genes in cHL, at least one mutation was detected in 236/275 patients (86%). B-symptoms, erythrocyte sedimentation rate, and advanced stages were significantly associated with the level of ctDNA at diagnosis. mutations (19/275, 7%) were strongly associated with inadequate response at early response assessment. mutations were associated with a higher risk of relapse. The presence of detectable ctDNA after two cycles of chemotherapy (10%) was a strong and independent prognostic marker of relapse. - Source: PubMed
Publication date: 2026/04/20
Simonin MathieuViennot MathieuHaouy StéphanieDucassou StéphaneCurtillet CatherineGarnier NathaliePhulpin AuréliePaillard CatherineRigaud CharlotteCouec Marie-LaureCarausu LianaBonneau JacinthePellier IsabelleBarbati MelissaMillot FrédéricDourthe Marie-ÉmilieKanold JustinaSchneider PascaleStephan Jean-LouisLeglise CamillePluchart ClaireViailly Pierre-JulienMichel VictorBoudjemaa SabahJonca BénédicteLeblanc ThierryLandman-Parker JudithJardin Fabrice - Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies that pose a serious health threat. Current therapies include symptomatic treatments for low-risk and hypomethylating agents for high-risk MDS. However, many patients develop resistance to hypomethylating drugs. (Exportin 1) XPO1 inhibition has shown efficacy in inducing tumor cell death by blocking the nuclear export of oncogenes; nevertheless, the role of XPO1 inhibition in MDS remains unexplored. - Source: PubMed
Publication date: 2026/04/20
Liu XiaohanHuang LeiWang JunzhuGuo YixuanShen HongliZhao XianghongYue LanzhuLiu ZhaoyunFu Rong - The canine transmissible venereal tumor (CTVT) is a naturally occurring clonal cancer that offers a unique model to study tumor evolution, immune evasion, and chemoresistance. Although vincristine induces complete remission in most cases, some tumors show partial response or resistance, and the molecular drivers of this variability remain unclear. While genomic and epigenetic studies have implicated multidrug resistance and immune modulation, transcriptional mechanisms underlying therapeutic outcomes are not fully characterized. - Source: PubMed
Publication date: 2026/04/15
López-Valbuena Fabián DOsorio-Zambrano William FDebiaso Rossi André LMontoya-Flórez Luis MRocha Noeme S - Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive subtype of liposarcoma, driven by a core transcriptional regulatory circuitry (CRC) that sustains tumor proliferation. This malignancy poses considerable clinical challenges, marked by high postoperative recurrence and metastatic potential, alongside a lack of effective targeted therapies. In this study, we establish that KPT-330 (Selinexor), a selective inhibitor of exportin 1 (XPO1), effectively compromises DDLPS cell viability by perturbing CRC homeostasis. Mechanistically, we demonstrate that KPT-330 attenuates the cellular translation machinery in a biphasic manner: initially, it disrupts translation initiation by suppressing eukaryotic translation initiation factor 4E phosphorylation and eukaryotic translation initiation factor 4 F complex assembly; subsequently, it impedes translation elongation by inhibiting the nuclear export of ribosomal large subunit proteins. Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS. - Source: PubMed
Publication date: 2026/04/16
Fan XiaoruiZhang YingYang ZhengmingTan Tuan ZeaHuang XingzeZheng SuyaLiu JiyangXie LongTao TingLee Victor KwanminYu ChaoKoeffler H PhillipChen YeXu Liang